Clinical trial
A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults
NCT05281263 is registered in ClinicalTrials.gov with Blue Lake Biotechnology Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults
- Lead sponsor
- Blue Lake Biotechnology Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 20, 2022
- Completion date
- May 3, 2023
- Enrollment
- 30 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.